1. Stuetz A, Baumann K, Grassberger M, et al. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol. 2006;141(3):199–212.
2. Protopic® (tacrolimus) ointment 0.03% and ointment 0.1% [US prescribing information]. Deerfield: Fujisawa Healthcare, Inc. 2000.
3. Elidel® (pimecrolimus) cream 1% [US prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation. 2010.
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Protopic NDA 50-777 approval letter. December 8, 2000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50777_Protopic_Approv.pdf . Accessed 23 Jan 2012.
5. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 approval letter. December 13, 2001. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-302_ELIDEL_Approv.pdf . Accessed 23 Jan 2012.